newsfilter
← Latest News
GlobeNewswire·

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

  • Instil Bio, Inc. reported fourth quarter & full year 2025 financial results & provided a corporate update on March 27, 2026.
  • Subsidiary Axion Bio discontinued clinical development of AXN-2510 in January 2026 & terminated its license agreement with ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
  • The company is pursuing acquisitions & in-licensing opportunities across multiple therapeutic areas to advance its strategic development phase.
  • Instil held $76.3 million in cash, cash equivalents, restricted cash, & marketable securities as of December 31, 2025, expected to fund operations beyond 2027.
  • Research & development expenses were $3.5 million for the fourth quarter & $24.7 million for the full year 2025.
  • General & administrative expenses totaled $6.1 million for the fourth quarter & $27.2 million for the full year 2025.
  • Restructuring & impairment charges were nil for the fourth quarter & $16.6 million for the full year 2025.
  • Net loss per share was $1.21 for the fourth quarter & $10.70 for the full year 2025.
  • Non-GAAP net loss per share was $0.97 for the fourth quarter & $6.91 for the full year 2025.
  • The company stated there is no assurance regarding specific transactions & will not provide further updates unless a deal is approved.